Pfizer Pakistan Limited and Pakistan Bait-ul-Mal, Government of Pakistan signed a Memorandum of Understanding (MoU) in January, 2019 – by virtue of this collaboration, Pfizer Pakistan and Pakistan Bait-ul-Maal, Government of Pakistan will support patient diagnosed with Cancer and are under critical care requiring novel treatments which are beyond conventional therapies from across Pakistan. The signing ceremony was held in Islamabad. This collaboration is part of Pfizer’s patient access program ‘MASEEHA’, an initiative to broaden access to Pfizer critical care and cancer medicines.
Must Read: Ahead of the January 28th launch, we see the design and features of Galaxy M20
Syed Wajeeh, Country Manager of Pfizer Pakistan, in his message at the MoU inking ceremony said, “We are very pleased to share that we are making significant investments in patient’s access program in collaboration with Pakistan Bait-ul-Maal, Government of Pakistan. The MoU stands out as an excellent example of cooperation between these two organizations in an area of public health for those patients who don’t have access to these crucial medicines to enhance their quality of life.
Ahead of the January 28th launch, we see the design and features of Galaxy M20
Aon Abbas Buppi, Managing Director Bait-ul-Mal, Government of Pakistanrecognized the importance of this partnership for the betterment of the society and especially for those deserving patients who do not have the financial support for purchasing these medicines. He further elaborated that the overall objective was to provide medical assistance to the deserving for better patient management care across Pakistan.
